← Back to Search

Janus Kinase (JAK) Inhibitor

Upadacitinib for Ulcerative Colitis

Phase 3
Recruiting
Research Sponsored by AbbVie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 52
Awards & highlights

Summary

This trial will assess the safety and effectiveness of Upadacitinib in treating pediatric UC. It will involve 2 periods, 8 wk induction, 44 wk double-blind maintenance, 260 wk open-label extension. 110 participants worldwide will take part.

Who is the study for?
This trial is for pediatric patients with moderate to severely active Ulcerative Colitis who haven't responded well to other treatments like corticosteroids, immunosuppressants, or biologics. They must have certain levels of disease activity and inflammation in the colon. Pregnant or breastfeeding individuals, or those planning pregnancy during the study period are excluded, as are those previously treated with JAK inhibitors.
What is being tested?
The trial tests Upadacitinib's safety and effectiveness in children with UC over two periods: an initial 8-week phase where everyone knows they're getting the drug followed by a 44-week phase where participants don't know their dose. This leads into a long-term extension for monitoring. The treatment involves daily oral tablets or solution.
What are the potential side effects?
While not explicitly listed here, common side effects of Upadacitinib may include infections due to immune system suppression, increased cholesterol levels, liver enzyme elevations indicating potential liver injury, gastrointestinal perforations (holes), and allergic reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 52
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 52 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percentage of Participants Achieving AMS Clinical Remission Among Week 8 Responders per AMS (Period 1)
Percentage of Participants Achieving Adapted Mayo score (AMS) Clinical Remission (Period 1)
Secondary study objectives
Percentage of Participants Achieving AMS Clinical Remission Among Week 8 Remitters per AMS (Period 1)
Percentage of Participants Achieving AMS Clinical Response (Period 1)
Percentage of Participants Achieving AMS Clinical Response Among Week 8 Responders per AMS (Period 1)
+6 more

Side effects data

From 2023 Phase 3 trial • 657 Patients • NCT03086343
24%
COVID-19
15%
URINARY TRACT INFECTION
14%
NASOPHARYNGITIS
11%
UPPER RESPIRATORY TRACT INFECTION
10%
RHEUMATOID ARTHRITIS
9%
HYPERTENSION
9%
HERPES ZOSTER
7%
BACK PAIN
6%
ALANINE AMINOTRANSFERASE INCREASED
6%
NAUSEA
6%
BRONCHITIS
6%
ASPARTATE AMINOTRANSFERASE INCREASED
6%
COUGH
6%
BLOOD CREATINE PHOSPHOKINASE INCREASED
6%
ARTHRALGIA
5%
WEIGHT INCREASED
5%
HYPERCHOLESTEROLAEMIA
4%
HEADACHE
4%
INFLUENZA
4%
OSTEOARTHRITIS
4%
FALL
4%
DEPRESSION
4%
ANAEMIA
3%
NEUTROPENIA
3%
COVID-19 PNEUMONIA
3%
EAR INFECTION
3%
SPINAL OSTEOARTHRITIS
3%
VITAMIN D DEFICIENCY
3%
CYSTITIS
3%
RESPIRATORY TRACT INFECTION
3%
PHARYNGITIS
3%
SINUSITIS
3%
GREATER TROCHANTERIC PAIN SYNDROME
3%
DIARRHOEA
3%
VOMITING
3%
FATIGUE
3%
PYREXIA
3%
HEPATIC STEATOSIS
3%
GASTROENTERITIS
2%
ANXIETY
2%
GASTRITIS
2%
LATENT TUBERCULOSIS
2%
PNEUMONIA
2%
INSOMNIA
2%
SCIATICA
2%
DYSPEPSIA
1%
MITRAL VALVE INCOMPETENCE
1%
DERMATITIS ALLERGIC
1%
HIP FRACTURE
1%
IRON DEFICIENCY ANAEMIA
1%
BLOOD PRESSURE INCREASED
1%
CARPAL TUNNEL SYNDROME
1%
PULMONARY MASS
1%
PRURITUS
1%
CATARACT
1%
ABDOMINAL PAIN
1%
MUSCULOSKELETAL CHEST PAIN
1%
PARAESTHESIA
1%
SYNCOPE
1%
SEPTIC SHOCK
1%
PULMONARY EMBOLISM
1%
TOOTH INFECTION
1%
TOOTH FRACTURE
1%
PHARYNGITIS STREPTOCOCCAL
1%
VIRAL UPPER RESPIRATORY TRACT INFECTION
1%
ATRIAL FIBRILLATION
1%
PLEURAL EFFUSION
1%
TACHYCARDIA
1%
TINNITUS
1%
PERIPHERAL SWELLING
1%
ASYMPTOMATIC COVID-19
1%
HERPES SIMPLEX
1%
PERIODONTITIS
1%
CONTUSION
1%
BLOOD CREATININE INCREASED
1%
BLOOD TRIGLYCERIDES INCREASED
1%
HAEMOGLOBIN DECREASED
1%
HEPATIC ENZYME INCREASED
1%
LIVER FUNCTION TEST INCREASED
1%
OSTEOPENIA
1%
DIZZINESS
1%
RENAL CYST
1%
DYSPHONIA
1%
NASAL CONGESTION
1%
RHINORRHOEA
1%
COSTOCHONDRITIS
1%
MUSCLE SPASMS
1%
OSTEOPOROSIS
1%
ASTHMA
1%
DEVICE DISLOCATION
1%
TRICUSPID VALVE INCOMPETENCE
1%
GLAUCOMA
1%
CONSTIPATION
1%
CHOLELITHIASIS
1%
LOCALISED INFECTION
1%
ONYCHOMYCOSIS
1%
ORAL CANDIDIASIS
1%
DECREASED APPETITE
1%
DIABETES MELLITUS
100%
80%
60%
40%
20%
0%
Study treatment Arm
Period 2, Primary Cohort: Upadacitinib 15 mg QD/Upadacitinib 15 mg QD
Period 2, 30 mg Cohort: Abatacept/Upadacitinib 30 mg QD/Upadacitinib 15 mg QD
Period 1, 30 mg Cohort: Upadacitinib 30 mg QD
Period 2, 30 mg Cohort: Upadacitinib 30 mg QD/Upadacitinib 30 mg QD
Period 2, Primary Cohort: Abatacept/Upadacitinib 15 mg QD
Period 2, 30 mg Cohort: Abatacept/Upadacitinib 30 mg QD
Period 2, 30 mg Cohort: Upadacitinib 30 mg QD/Upadacitinib 30 mg QD/Upadacitinib 15 mg QD
Period 1, Primary and 30 mg Cohorts: Abatacept
Period 1, Primary Cohort: Upadacitinib 15 mg QD

Trial Design

5Treatment groups
Experimental Treatment
Group I: Period 2- Open Label Long Term Extension Phase Arm BExperimental Treatment1 Intervention
Clinical non-responders in US after Period 1 induction phase or clinical responders with loss of response during maintenance phase will receive upadacitinib Dose B daily for up to 260 weeks in OLE Period 2.
Group II: Period 2- Open Label Long Term Extension Phase Arm AExperimental Treatment1 Intervention
Clinical non-responders outside of US after Period 1 induction phase will receive upadacitinib Dose A daily for 8 week extended induction phase in open label long term extension (OLE) Period 2. Clinical responders from extended induction phase in OLE will receive upadacitinib Dose B daily for up to 252 weeks in OLE period 2.
Group III: Period 2- Long Term Extension Phase Arm CExperimental Treatment1 Intervention
Clinical responders who complete Period 1 through Week 52 will receive upadacitinib Dose C daily for up to 260 weeks in OLE Period 2.
Group IV: Period 1- Open Label Induction PhaseExperimental Treatment1 Intervention
All participants in open label induction phase of Period 1 will receive upadacitinib Dose A for 8 weeks based on body weight.
Group V: Period 1- Double Blind Maintenance PhaseExperimental Treatment1 Intervention
Clinical responders at the end of open label induction phase of Period 1 will be randomly assigned to receive either upadacitinib Dose B or Dose C for 44 weeks based on body weight.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Upadacitinib
2014
Completed Phase 3
~9710

Find a Location

Who is running the clinical trial?

AbbVieLead Sponsor
1,004 Previous Clinical Trials
513,668 Total Patients Enrolled
32 Trials studying Ulcerative Colitis
22,266 Patients Enrolled for Ulcerative Colitis
ABBVIE INC.Study DirectorAbbVie
430 Previous Clinical Trials
155,988 Total Patients Enrolled
18 Trials studying Ulcerative Colitis
17,152 Patients Enrolled for Ulcerative Colitis

Media Library

Upadacitinib (Janus Kinase (JAK) Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05782907 — Phase 3
Ulcerative Colitis Research Study Groups: Period 1- Open Label Induction Phase, Period 1- Double Blind Maintenance Phase, Period 2- Open Label Long Term Extension Phase Arm A, Period 2- Open Label Long Term Extension Phase Arm B, Period 2- Long Term Extension Phase Arm C
Ulcerative Colitis Clinical Trial 2023: Upadacitinib Highlights & Side Effects. Trial Name: NCT05782907 — Phase 3
Upadacitinib (Janus Kinase (JAK) Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05782907 — Phase 3
~73 spots leftby Aug 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top